GT Biopharma, Inc.
www.gtbiopharma.comUsing our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE) platform technology. (NASDAQ: GTBP)
Read more
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE) platform technology. (NASDAQ: GTBP)
Read more
Country
State
California
Industry
Employees
1-10
Founded
1973
Social
Employees statistics
View all employeesPotential Decision Makers
Vice President Cmc and Pharmaceutical Sciences
Email ****** @****.comPhone (***) ****-****Chairman , Scientific Advisory Board
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Chief Financial Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(15)
Reach decision makers at GT Biopharma, Inc.
Free credits every month!
GT Biopharma, Inc. FAQ
United States
Biotechnology Research
